Bioreactors for Development of Tissue Engineered Heart Valves
Bioreactors for Development of Tissue Engineered Heart Valves
复制标题
DOI：
10.1007/s10439-010-0148-6
复制
发表时间：
2010-11-01
影响因子：
3.8
通讯作者：
Yoo, James J.
中科院分区：
文献类型：
--
作者：
Berry, Joel L.;Steen, Julie A.;Yoo, James J.
全世界每年有数百万人被诊断出患有瓣膜心脏病，导致数十万例瓣膜置换手术。人工瓣膜置换设计用于纠正瓣口狭窄或回流。虽然常用，但这些疗法有严重的缺点，包括与长期抗凝相关的并发症，以及需要重复手术的耐受性有限。对于大多数心脏外科医生来说，理想的替代物具有广泛的可获得性和技术可植入性，具有正常的血流动力学性能，结构退化、血栓栓塞症和心内膜炎的风险较低，并且对儿科患者具有增长潜力。组织工程心脏瓣膜有望成为一种性能优于现有瓣膜替代物的可行替代品。开发组织工程心脏瓣膜的一个重要组成部分是生物反应器。正是在生物反应器内，支架和细胞逐渐适应要更换的瓣膜的生化和机械环境。
Millions of people worldwide are diagnosed each year with valvular heart disease, resulting in hundreds of thousands of valve replacement operations. Prosthetic valve replacements are designed to correct narrowing or backflow through the valvular orifice. Although commonly used, these therapies have serious disadvantages including morbidity associated with long-term anticoagulation and limited durability necessitating repeat operations. The ideal substitute would be widely available and technically implantable for most cardiac surgeons, have normal hemodynamic performance, low risk for structural degeneration, thrombo-embolism and endocarditis, and growth potential for pediatric patients. Tissue engineered heart valves hold promise as a viable substitute to outperform existing valve replacements. An essential component to the development of tissue engineered heart valves is a bioreactor. It is inside the bioreactor that the scaffold and cells are gradually conditioned to the biochemical and mechanical environment of the valve to be replaced.